Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight
21. Februar 2022 13:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key...
Hemispherx Biopharma's Ampligen(R) Cited at Barcelona Vaccine & Active Immunotherapeutics Forum 2011
12. Mai 2011 13:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 12, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced that Ampligen® will be featured in a discussion of...